Daré Bioscience to Participate at the Women’s Health Innovation Series: Contraception Innovation Summit to be held Virtual...
February 16 2021 - 8:00AM
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s
health innovation, today announced that Sabrina Martucci
Johnson, its President and Chief Executive Officer, will
participate in a live panel discussion titled,
The
Evolution of Birth Control: Considerations from
Product Development to End-User Adoption
from Leading Innovators, at 12:30 p.m. EST / 9:30
a.m. PST on Tuesday, February 23, 2021, at the Women’s Health
Innovation Series: Contraception Innovation Summit, which will be
held virtually.
The panel will discuss the opportunities and
challenges faced by innovators when advancing new methods of birth
control. As a featured speaker, Ms. Johnson will share Daré’s
commitment to addressing unmet needs in contraception and the
Company’s own journey with three innovative product candidates
under development: Ovaprene®, an investigational hormone-free,
monthly contraceptive that the Company is advancing towards a
pivotal contraceptive study and whose U.S. commercial
rights are under a license agreement with Bayer; DARE-LARC1, an
investigational user-controlled long acting reversible
levonorgestrel drug delivery system designed to store in a single
implant and precisely deliver hundreds of therapeutic doses over
months or years, whose development has been supported by $20.5
million in grant funding from the Bill & Melinda Gates
Foundation; and ORB-204 and ORB-214, investigational injectable
formulations of etonogestrel being developed as longer-acting (6-
and 12-months) methods of contraception with a more predictable
return to fertility compared to currently marketed injectable
contraceptive products.
The Contraception Innovation Summit is part of
the 2021 Women’s Health Innovation Series. The Summit is about
putting women at the center of contraceptive research,
innovations, and education to improve women’s contraceptive
journeys throughout their lives. Participants will include a
leading network of pharma, biotech, medical device companies,
start-ups, investors, researchers, and health care providers
driving innovation at the convergence of healthcare and
technology.
Find out more by downloading the
agenda
About Daré Bioscience
Daré Bioscience is a clinical-stage
biopharmaceutical company committed to the advancement of
innovative products for women’s health. The company’s mission is to
identify, develop and bring to market a diverse portfolio of
differentiated therapies that expand treatment options, improve
outcomes and facilitate convenience for women, primarily in the
areas of contraception, vaginal health, sexual health, and
fertility.
Daré’s product portfolio includes potential
first-in-category candidates in clinical development: Ovaprene®, a
hormone-free, monthly contraceptive intravaginal ring
whose U.S. commercial rights are under a license
agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream
formulation of sildenafil to treat female sexual arousal disorder
utilizing the active ingredient in Viagra®; DARE-BV1, a unique
hydrogel formulation of clindamycin phosphate 2% to treat bacterial
vaginosis via a single application; and DARE-HRT1, a combination
bio-identical estradiol and progesterone intravaginal ring for
hormone replacement therapy following menopause. To learn more
about Daré’s full portfolio of women’s health product candidates,
and mission to deliver differentiated therapies for women, please
visit www.darebioscience.com.
Daré may announce material information about its
finances, product candidates, clinical trials and other matters
using the Investors section of its website
(http://ir.darebioscience.com), SEC filings, press
releases, public conference calls and webcasts. Daré will use these
channels to distribute material information about the company, and
may also use social media to communicate important information
about the company, its finances, product candidates, clinical
trials and other matters. The information Daré posts on its
investor relations website or through social media channels may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts in the Investors section of its website and
to follow these Twitter accounts: @SabrinaDareCEO and
@DareBioscience. Any updates to the list of social media channels
the company may use to communicate information will be posted on
the investor relations page of Daré’s website mentioned above.
Contact:Investors on behalf of
Daré Bioscience, Inc.:Tom MastersonAllele Capital
Partnerstmasterson@allelecapital.com646.573.3216
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024